A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors.
Shinji KumeHiroshi MaegawaPublished in: Journal of diabetes investigation (2022)
SGLT2 inhibitors may have a potential to stop the decline of renal function independent of the stage of albuminuria in diabetic kidney disease, and can be a new light in the post-RAS inhibitor era.